A Beta-Blocker Question the Varices Don't Actually Answer
A single patient whose chronic anemia has already been traced to the right disease, just not yet to the right treatment plan. The disagreement is about how to start a first-ever drug safely, not about whether it belongs in his regimen.
F.E., a 63-year-old retired bus driver with cirrhosis from longstanding hepatitis C — cured with direct-acting antivirals four years ago, though the cirrhosis itself remains — has needed iron infusions twice in the past year for anemia his hepatologist has now traced specifically to portal hypertensive gastropathy rather than his previously banded esophageal varices, which haven't bled since treatment. Endoscopy shows the classic "snake-skin" mucosal pattern of PHG diffusely through his gastric body and fundus, without any actively bleeding lesion visible on the day of the exam — chronic, low-grade oozing rather than a discrete event, which is exactly why it shows up as slow anemia rather than an acute bleed he'd have come to the ED for. His two iron infusions this past year weren't originally attributed to his stomach at all — the first was worked up as possible occult colonic bleeding before a repeat upper endoscopy, prompted by his hepatologist's own persistence rather than a new symptom, finally identified the actual gastric source.
It's tempting to treat this as the same decision already made for his varices, but portal hypertensive gastropathy and esophageal varices are mechanistically related — both downstream consequences of portal hypertension — yet pharmacologically distinct questions with separate evidence bases. Variceal bleeding prophylaxis with nonselective beta-blockade is one of the best-established interventions in hepatology, reducing portal pressure through combined beta-1-mediated cardiac output reduction and beta-2-mediated splanchnic vasoconstriction, unopposed alpha-adrenergic activity narrowing splanchnic blood flow specifically. PHG-related bleeding shares the same underlying portal-pressure mechanism, and NSBB therapy does have real, if smaller and less extensively trialed, evidence supporting its use for reducing PHG-related bleeding specifically — not an assumption carried over from the variceal literature, but its own distinct body of evidence that happens to point toward the same drug class. What complicates a simple "start the beta-blocker" answer is that he isn't currently on one — his varices were managed by banding alone, and his portal pressure has never been directly measured by hepatic venous pressure gradient — so starting NSBB therapy now would be a first exposure in a patient whose baseline hemodynamic reserve, relevant given his cirrhosis's own effect on cardiac output, hasn't been formally characterized.
The same drug class, a different disease, and a first dose to get right
Portal hypertensive gastropathy has its own real evidence base for nonselective beta-blockade — this isn't the variceal literature carried over by assumption, it's a distinct body of trial data pointing at the same drug class for a related but separate mechanism.
Given his transfusion-requiring anemia is a real, ongoing clinical problem, I'd start carvedilol — its added alpha-1 blockade gives somewhat greater portal-pressure reduction than traditional NSBBs, and it's become the preferred first agent in a lot of recent cirrhosis practice.
I agree the indication is real and well-supported — I'm not questioning whether he should be on an NSBB.
What I'd flag is that he's never taken a beta-blocker before, and his hepatic reserve is only moderate. Carvedilol's alpha-1-mediated vasodilation, on top of its beta-blockade, is a real added hypotension risk specifically on a first exposure where we have no baseline sense of his tolerance. Propranolol has a longer track record of predictable, gradual titration in exactly this situation.
That's a fair caution — carvedilol's greater effect size doesn't help him if the first dose drops his pressure further than his reserve can absorb.
I'd start propranolol at a low, conservative dose with close blood pressure monitoring, and revisit carvedilol later once we have a real sense of how he tolerates beta-blockade at all — the disease-specific rationale for treating his PHG holds either way; this is about how to start safely, not whether to start.
Propranolol started at a low, conservative dose with close blood pressure monitoring, given his lack of prior beta-blocker exposure and moderate hepatic reserve, with a plan to reassess and consider transitioning to carvedilol later once his tolerance for beta-blockade is better established.
Agreed by both; the disagreement was entirely about sequencing a safe first exposure, not about whether nonselective beta-blockade itself was the right call for his portal hypertensive gastropathy.